Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $68.00 price target on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $63.00 price target on the stock.
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate [Yahoo! Finance]
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]